Immunicum AB (publ) develops therapeutic cancer vaccines.
Excellent balance sheet and overvalued.
Share Price & News
How has Immunicum's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1YG's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 1YG exceeded the German Biotechs industry which returned 3.7% over the past year.
Return vs Market: 1YG exceeded the German Market which returned 6.1% over the past year.
Price Volatility Vs. Market
How volatile is Immunicum's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Immunicum undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 1YG's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 1YG's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 1YG is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 1YG is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1YG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1YG is good value based on its PB Ratio (3x) compared to the DE Biotechs industry average (3.2x).
How is Immunicum forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1YG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1YG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1YG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 1YG's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 1YG's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1YG's Return on Equity is forecast to be high in 3 years time
How has Immunicum performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1YG is currently unprofitable.
Growing Profit Margin: 1YG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 1YG is unprofitable, and losses have increased over the past 5 years at a rate of -27.9% per year.
Accelerating Growth: Unable to compare 1YG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1YG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: 1YG has a negative Return on Equity (-49.13%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Immunicum's financial position?
Financial Position Analysis
Short Term Liabilities: 1YG's short term assets (SEK303.6M) exceed its short term liabilities (SEK30.2M).
Long Term Liabilities: 1YG's short term assets (SEK303.6M) exceed its long term liabilities (SEK849.0K).
Debt to Equity History and Analysis
Debt Level: 1YG's debt to equity ratio (0.3%) is considered satisfactory.
Reducing Debt: 1YG's debt to equity ratio has reduced from 1% to 0.3% over the past 5 years.
Inventory Level: 1YG has a low level of unsold assets or inventory.
Debt Coverage by Assets: 1YG's debt is covered by short term assets (assets are 357.1x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1YG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 1YG has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Immunicum's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate 1YG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 1YG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1YG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1YG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1YG's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Alex Karlsson-Parra (69yo)
Mr. Alex Karlsson-Parra, M.D., Ph.D. is the Founder of Immunicum AB and has been its Chief Scientific Officer since 2008. He serves as Acting Chief Executive Officer at Immunicum AB (publ) since December 1 ...
|Advisor Contracts||4yrs||kr161.70k||no data|
|Founder||0.2yrs||no data||0.67% SEK520.9k|
|Chief Financial Officer||2yrs||no data||0.023% SEK17.6k|
|COO & Senior Director of Business Development||0.2yrs||no data||0.014% SEK11.1k|
|Head of Regulatory affairs & QA||4.1yrs||no data||0.032% SEK24.7k|
|Head of CMC||2.3yrs||no data||0.0092% SEK7.1k|
Experienced Management: 1YG's management team is considered experienced (2.2 years average tenure).
|Independent Director||4.2yrs||kr68.75k||no data|
|Independent Director||3.3yrs||kr37.50k||0.0043% SEK3.4k|
|Chairman||1.8yrs||no data||0.019% SEK14.7k|
|Independent Director||3.3yrs||kr43.75k||no data|
|Independent Director||3.3yrs||kr31.25k||no data|
|Member of Scientific Advisory Board||1.4yrs||no data||no data|
|Member of Scientific Advisory Board||1.4yrs||no data||no data|
Experienced Board: 1YG's board of directors are considered experienced (3.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 1YG insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 73.9%.
Immunicum AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: Immunicum AB (publ)
- Ticker: 1YG
- Exchange: DB
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: kr817.402m
- Listing Market Cap: kr77.300m
- Shares outstanding: 92.26m
- Website: https://immunicum.se
Number of Employees
- Immunicum AB (publ)
- Östermalmstorg 5
- Stockholm County
- 114 42
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|IMMU||OM (OMX Nordic Exchange Stockholm)||Yes||Ordinary Shares||SE||SEK||Apr 2013|
|1YG||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Apr 2013|
|IMMUS||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||SEK||Apr 2013|
Immunicum AB (publ) develops therapeutic cancer vaccines. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II clinical trials for the treatment of head and neck cancer, non-small cell lung cancer, and gastric cancer, as well as is in a Phase I/II clinical trials to treat liver cancer and gastrointestinal stromal tumors. The company’s products also comprise IMM-2 platform, which is in preclinical trials is transfected with an adenoviral vector to deliver tumor antigens directly to the cells; and IMM-3 platform, which is in a preclinical phase study optimized CAR-T expansion protocol for improved anti-cancer activity. Immunicum AB (publ) has a collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate ilixadencel in combination with avelumab in multi-indication Phase Ib/II study. The company is headquartered in Stockholm, Sweden.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/25 23:37|
|End of Day Share Price||2020/02/25 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.